{"ticker": {"uuid": "00e1f896-7570-4779-ad10-c94738122090", "symbol": "ENTA", "name": "Enanta Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. \u2013 NASDAQ:ENTA", "summary": "The article provides financial data for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), specifically focusing on its enterprise value to EBITDA forward. It indicates the stock market status as closed with no trades. The document highlights the data sources and copyright information ", "url": "https://www.tradingview.com/symbols/NASDAQ-ENTA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-15T00:13:31", "published_display": "15 Jul 2026 00:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. \u2013 DUS:9EP", "summary": "The article focuses on the enterprise value to EBIT forward for Enanta Pharmaceuticals, Inc. (DUS:9EP) as listed on the Dusseldorf Stock Exchange. It provides a financial overview, though no specific values are present, and highlights the company's listing within the Health Techn", "url": "https://www.tradingview.com/symbols/DUS-9EP/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T15:09:30", "published_display": "08 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. \u2013 SWB:9EP", "summary": "This page on TradingView provides financial information for Enanta Pharmaceuticals, Inc. (SWB:9EP), focusing on its enterprise value to forward EBITDA. The content is primarily an outline for financial data and analysis tools available on the platform, without detailed numerical ", "url": "https://www.tradingview.com/symbols/SWB-9EP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T13:40:53", "published_display": "08 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. \u2013 DUS:9EP", "summary": "This page provides financial data, specifically the Enterprise Value to EBITDA forward, for Enanta Pharmaceuticals, Inc. (9EP) traded on the Dusseldorf Stock Exchange. It appears to be a financial data snippet from TradingView, offering a quick overview without detailed analysis ", "url": "https://www.tradingview.com/symbols/DUS-9EP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T11:39:54", "published_display": "08 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals outlines its antiviral pipeline as investors weigh long-term prospects", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNbjR3dWJPN0psTzBxWE1iZEVlUG1DdjJFV0Etc1R4RFl4VXlQRVk2Vlp3OUhQUm5nRk4wNEJCa0ctelhCcHJrWGF0UElrRG1HMXJ3MDg5TDlZaUQ5MXI2dVdhdDhnTG1LLWlYNjVWZTRFaWw4WnZMek10dFZ6YWZoQWhaM3FkTlpzX3MyTnNiSlN2UW9zazJKd2FnRERtdVZSOUpyd09iRmtXa3YyV3c5YzFnU1JWR2lWV29ydThsNmtsRUZxcnMzaS1UYkg?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-07T16:02:36+00:00", "published_display": "07 Jul 2026 16:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. \u2013 GETTEX:9EP", "summary": "This page from TradingView displays financial information for Enanta Pharmaceuticals, Inc. (GETTEX:9EP), specifically focusing on its Enterprise Value to EBITDA forward metric. The content indicates that the market is currently closed, and no trades have occurred for this stock.", "url": "https://www.tradingview.com/symbols/GETTEX-9EP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T12:09:26", "published_display": "06 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. \u2013 GETTEX:9EP", "summary": "This page provides financial data for Enanta Pharmaceuticals, Inc. (GETTEX:9EP), specifically focusing on its enterprise value to EBIT forward. The content is hosted on TradingView, a platform offering various financial tools and market data, and includes legal disclaimers about ", "url": "https://www.tradingview.com/symbols/GETTEX-9EP/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T10:42:09", "published_display": "06 Jul 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals outlines its antiviral pipeline. Focus on long-term opportunities for ENTA st", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOTGhTa3U1UnlESzZjSGM3U3lqX0tkV0dGTDVST3ptUmhmVHo2TVhGODhXZW5mdXg4ODgwMHBJWXFCRTdhMHQ1bmVUZ3hpdDIxbUVrbkt3Qng2dEtHVGZxZzl1SnhYaERpNGVYZVBFdEVKaEc1M1I4cWNzWGo3Tm15WXJpRkUtcENIQWZQc2pUZURBbV9RRFVkVnJnMS1WY1R0bWFzekNHNGxDcXlScUJ5TFJ1YTRKNDNzTEVtNXZ1cFVZVC1MSTR5MkFDTVY?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-03T14:18:42+00:00", "published_display": "03 Jul 2026 14:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 Enanta Pharmaceuticals Inc For: 2 July By Investing.com", "summary": "This article announces the filing of Form 424B5 for Enanta Pharmaceuticals Inc. on July 2nd. It provides basic information about the filing and includes irrelevant market data and news headlines, typical of an Investing.com article.", "url": "https://ca.investing.com/news/stock-market-news/form-424b5-enanta-pharmaceuticals-inc-for-2-july-93CH-4719116", "source_name": "Investing.com Canada", "published_at": "2026-07-03T00:12:21", "published_display": "03 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Enters $75 Million At-the-Market Stock Offering Agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPMHBSNkZjaFl0UHJ5c3hnUlM2NkZESHZOTFYydDlJS0lEU1FsRXI1VVBHVlpWOUpMem5VQjFjZlZmZW1adG9QVTZIN1RKS1h5eEJmV2ZXS2hybXRZdFJtbUhiVUlZWU9RaFVnU3JBQVV2T1QwdDJBYnkycktPaEhhUm5PaVZQLXJuRlZsRlZMc2VtZUtLb29lOFZDSW95MGplQlFiUi1xV3Q?oc=5", "source_name": "Moomoo", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Enanta Pharmaceuticals, Inc. \u2013 NASDAQ:ENTA", "summary": "This page on TradingView.com focuses on the \"Price to sales forward\" metric for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). It provides financial data and an overview of the company's valuation, indicating information about the market performance and financial health of Enanta P", "url": "https://www.tradingview.com/symbols/NASDAQ-ENTA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T15:40:36", "published_display": "01 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Small Cap Comp Growth Benchmark", "summary": "Enanta Pharmaceuticals, Inc. (NasdaqGS: ENTA) has been added to the Russell Small Cap Comp Growth Benchmark, as well as the Russell 2500 Growth and Russell 2000 Growth Benchmarks. This inclusion indicates recognition of the company's growth potential within the small-cap market. ", "url": "https://www.marketscreener.com/news/enanta-pharmaceuticals-inc-nasdaqgs-enta-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdd81f721", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:10:48", "published_display": "29 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 2500 Growth Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQbEhtSklIZzliS1IwUm9BdkpMTlczSFJRUkZRRXNPWEt0Ti12dnBhWU92c0NobFhfRjNzM1BhNms2U2dIc0tlckVzbE9UYk5xS00xS3AwQjlzQjVRaEdYcnhVNzJRZUFOM0lTMlJwS2xyakxFWFE2THFSLU1vdE01a0NaRkFDdU9mU0d1WGdRWEh1UTNqT1BVUlFmaGRYbUJwR19OMkIyVnpjSlF3d1hieU1SSEJRZjl2cUxGbkx6cmMyWjI4ZTU0Z1pncFo?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 3000E Growth Benchmark", "summary": "Enanta Pharmaceuticals, Inc. (NasdaqGS: ENTA) has been added to the Russell 3000E Growth Benchmark. The clinical-stage biotechnology company, focused on virology and immunology, saw its stock rise by 4.09% to 14.00 USD. This inclusion highlights the company's growth potential and", "url": "https://www.marketscreener.com/news/enanta-pharmaceuticals-inc-nasdaqgs-enta-added-to-russell-3000e-growth-benchmark-ce7f5fdeda88f523", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T03:40:57", "published_display": "29 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Vance Terry", "summary": "This article is a statement of changes in beneficial ownership of securities for Enanta Pharmaceuticals, specifically pertaining to Director Vance Terry. It is a regulatory filing indicating transactions related to his holdings in the company.", "url": "https://www.moomoo.com/news/notice/306660384/enanta-pharmaceuticals-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-28T23:40:36", "published_display": "28 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals | SCHEDULE 13G/A: Others", "summary": "This article indicates that a SCHEDULE 13G/A filing related to Enanta Pharmaceuticals (ENTA) has been submitted into the public record. The filing is categorized under \"Others,\" suggesting a beneficial ownership report from a passive investor or another type of filer.", "url": "https://www.moomoo.com/news/notice/306757153/enanta-pharmaceuticals-schedule-13g-a-others", "source_name": "Moomoo", "published_at": "2026-06-28T23:38:58", "published_display": "28 Jun 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 3000 Growth Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPdWdhZ1AwbWp4TFpUcnlYbFF5cDhSSkh6UzUtck1RUVlQZXlsbm1lem9NZ3ZoSEdoYTRCOGZDbnpOaEdidl92clhKckZVYV9Nb096dVVLeGN1dzZCWjdQS2pQaThkbjFVVDB3bTZhZGFVeG0tcGRKYWxzY092dWJ5eEJ0aDg2WG14X2d4RHNRMHRPdHlmSzhNVHVUWGNrMlNLYXVhY1lCY1g3cEhBSW1pcTg2dWItelpvNURDeFZqSzZNbzJDRHdMWFFHSXQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ENTA)", "summary": "This article provides financial actuals and estimates for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), including stock price performance, analyst forecasts, earnings, revenue, and market capitalization. It highlights the company's historical stock prices, volatility, and upcoming", "url": "https://www.tradingview.com/symbols/NASDAQ-ENTA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:50", "published_display": "26 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Enanta Pharmaceuticals, Inc. \u2013 TRADEGATE:9EP", "summary": "This article focuses on the enterprise value to revenue forward for Enanta Pharmaceuticals, Inc. (TRADEGATE:9EP). It lists the company's trading information on the Tradegate Exchange, indicating that the market is currently closed with no trades. The piece is primarily a financia", "url": "https://www.tradingview.com/symbols/TRADEGATE-9EP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:50", "published_display": "26 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Enanta Pharmaceuticals, Inc. \u2013 NASDAQ:ENTA", "summary": "This article provides the \"Price to book forward\" for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). It is a finance-related snippet from TradingView, indicating a focus on financial metrics for the company. The content itself is minimalist, primarily showcasing the title and conte", "url": "https://www.tradingview.com/symbols/NASDAQ-ENTA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:50", "published_display": "26 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals, Inc. Actuals & Estimates (FWB:9EP)", "summary": "This article provides an overview of Enanta Pharmaceuticals, Inc. (FWB:9EP) financials, analyst forecasts, and historical stock performance. It includes details on past earnings, revenue, EBITDA, and provides predictions for future financial results, noting that the company does ", "url": "https://www.tradingview.com/symbols/FWB-9EP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T04:10:30", "published_display": "26 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENTA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Enanta Pharmaceuticals, Inc. (ENTA) stock, including analyst price targets, historical performance, and key financial data. Eight analysts have provided 1-year price forecasts, with a maximum estimate of $32.00 and a minimum of $14.00. The com", "url": "https://www.tradingview.com/symbols/NASDAQ-ENTA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T22:10:50", "published_display": "25 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Enanta Pharmaceuticals, Inc. \u2013 NASDAQ:ENTA", "summary": "This article displays the \"Price to earnings forward\" metric for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). It presents financial data for the company, accessible through TradingView, and includes general market and company information. The content primarily focuses on the stoc", "url": "https://www.tradingview.com/symbols/NASDAQ-ENTA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:10:04", "published_display": "25 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Enanta Pharmaceuticals, Inc. \u2013 TRADEGATE:9EP", "summary": "This article provides financial information for Enanta Pharmaceuticals, Inc. (TRADEGATE:9EP), specifically focusing on its price to book forward value. The data is available through TradingView, which aggregates market and reference data from various providers.", "url": "https://www.tradingview.com/symbols/TRADEGATE-9EP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T17:09:50", "published_display": "25 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?", "summary": "Enanta Pharmaceuticals (ENTA) saw its shares rally 5.2% after its partner, AbbVie, received European Commission approval for Maviret to treat acute hepatitis C. Enanta receives royalties from Maviret's sales. Despite the immediate bump, the stock's future strength is uncertain as", "url": "https://sg.finance.yahoo.com/news/enanta-pharmaceuticals-enta-moves-5-131300518.html", "source_name": "Market source", "published_at": "2026-06-24T13:39:50", "published_display": "24 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Files Appeal in Ongoing Patent Dispute With Pfizer Over Paxlovid", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/enanta-files-appeal-ongoing-patent-102036139.html", "source_name": "MT Newswires", "published_at": "2026-06-24T10:20:36+00:00", "published_display": "24 Jun 2026 10:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EC approves label expansion for Enanta\u2019s Maviret in acute HCV infection", "summary": "The European Commission (EC) has approved Maviret (glecaprevir/pibrentasvir) for treating acute hepatitis C virus (HCV) infection in adults and children aged three years and older. This approval makes Maviret the only treatment available in the EU for both acute and chronic HCV i", "url": "https://www.thepharmaletter.com/pharma-news/ec-approves-label-expansion-for-enanta-s-maviret-in-acute-hcv-infection", "source_name": "The Pharmaletter", "published_at": "2026-06-24T10:39:50", "published_display": "24 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Enanta Pharmaceuticals Inc For: 23 June", "summary": "This article reports on an SEC Form 8K filing by Enanta Pharmaceuticals Inc for June 23. It states that the information provided is not necessarily real-time or accurate and advises readers about the high risks associated with trading financial instruments and cryptocurrencies. T", "url": "https://m.uk.investing.com/news/stock-market-news/form-8k-enanta-pharmaceuticals-inc-for-23-june-93CH-4741365?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-24T04:39:50", "published_display": "24 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Enanta Pharmaceuticals Inc For: 23 June By Investing.com", "summary": "This article reports that Enanta Pharmaceuticals Inc. filed a Form 8K on June 23. The filing is an important regulatory disclosure for public companies. The article provides the title of the filing and mentions the company's stock symbol ENTA, which had a 4.09% increase.", "url": "https://ng.investing.com/news/stock-market-news/form-8k-enanta-pharmaceuticals-inc-for-23-june-93CH-2571085", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T22:39:53", "published_display": "23 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] ENANTA PHARMACEUTICALS INC Reports Material Event", "summary": "Enanta Pharmaceuticals, Inc. (ENTA) reported via an 8-K filing that the United States Court of Appeals for the Federal Circuit affirmed a prior summary judgment ruling, invalidating Enanta's U.S. Patent No. 11,358,953. This patent was related to Pfizer Inc.'s COVID-19 antiviral, ", "url": "https://www.stocktitan.net/sec-filings/ENTA/8-k-enanta-pharmaceuticals-inc-reports-material-event-55a5dd1ee466.html", "source_name": "Stock Titan", "published_at": "2026-06-23T22:10:50", "published_display": "23 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAFC Affirms Enanta Coronavirus Patent Invalid for Lack of Written Description Support in Provisional Application", "summary": "The U.S. Court of Appeals for the Federal Circuit (CAFC) has affirmed the invalidity of Enanta Pharmaceuticals, Inc.'s U.S. Patent 11,358,953 due to a lack of written description support in its provisional application. This decision means the patent cannot claim the earlier prior", "url": "https://ipwatchdog.com/2026/06/23/cafc-affirms-enanta-coronavirus-patent-invalid-lack-written-description-support-provisional-application/", "source_name": "IPWatchdog.com", "published_at": "2026-06-23T18:11:15", "published_display": "23 Jun 2026 18:11", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Enanta stock rating on FDA alignment", "summary": "H.C. Wainwright maintained a Buy rating and $20.00 price target for Enanta Pharmaceuticals (NASDAQ:ENTA) following the FDA's alignment on zelicapavir, which significantly reduces regulatory uncertainty for the RSV drug. Enanta also announced plans for late-stage clinical trials f", "url": "https://m.investing.com/news/analyst-ratings/hc-wainwright-reiterates-enanta-stock-rating-on-fda-alignment-93CH-4755287?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-23T12:11:09", "published_display": "23 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals\u2019 Partner AbbVie Receives European Commission Approval of MAVIRET\u00ae (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus", "summary": "Enanta Pharmaceuticals announced that its partner AbbVie received European Commission approval for MAVIRET\u00ae (glecaprevir/pibrentasvir) to treat acute Hepatitis C Virus (HCV) infection in adults and children aged 3 years and older. This makes MAVIRET the only EU-approved treatment", "url": "https://www.biospace.com/press-releases/enanta-pharmaceuticals-partner-abbvie-receives-european-commission-approval-of-maviret-glecaprevir-pibrentasvir-for-people-with-acute-hepatitis-c-virus", "source_name": "BioSpace", "published_at": "2026-06-23T11:11:09", "published_display": "23 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 89, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals\u2019 Partner AbbVie Receives European Commission Approval of MAVIRET", "summary": "The European Commission has approved MAVIRET (glecaprevir/pibrentasvir), developed by AbbVie with glecaprevir discovered by Enanta Pharmaceuticals, for treating acute Hepatitis C Virus (HCV) infection in adults and children aged 3 and older. This makes MAVIRET the only treatment ", "url": "https://www.businesswire.com/news/home/20260619262507/en/Enanta-Pharmaceuticals-Partner-AbbVie-Receives-European-Commission-Approval-of-MAVIRET-GlecaprevirPibrentasvir-for-People-with-Acute-Hepatitis-C-Virus", "source_name": "Business Wire", "published_at": "2026-06-23T09:11:09", "published_display": "23 Jun 2026 09:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Federal appeals court upholds invalidity of Enanta patent in Pfizer case", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQdHZibmZ3YVhHLVFyeFBRZzFib1ZZWVFOUkRGaWlCbFhvOVRjeWlvT0dkLUJRRFNRMEFGcHRBWmVDWDN1bjZrMUpZdU0zYmtsVDkxV1lhLTBVWVhqckNwejNkNF9oR2UtQzFfM0daajIzc0JYa1JLZ3REc19Qempaai01bng5ZUNMUVhKQ2NuSHc2ZUZ6RmpBZi1TOHB2ZWQwM1dfTHdvaHpka1JyUkN6c1lHOUdkaEo0SEtGSTN5Wktza1pjWk5nRkVXdTEzdw?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta partner AbbVie secures EU approval for MAVIRET in acute HCV", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOSEVhblhLU19TS3NDTzlER2FnNGEzc0xQWnlhVmV3ZTBMNmZzX3Z1c0wwamU5eDRGeTNrWWRqdjVWMHUtc3U4M3NRSWdhanBYYkVabnFmY2ZCbjRhSExqMDZWVG9tTUN0LXlIcDFDNFFwTFhKeUZnZFREb0VNSENDYmFfZEVZVHNhOUxvQTBtOUZUWkZnYUdSSmVBMXItNDByWHlqOVNfcUxqUGVKS1hSQXFUWl9MV0tJRlJsWDdiRQ?oc=5", "source_name": "scanx.trade", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer patent win against Enanta over COVID pill upheld by appeals court", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQbUNZUG1EYndSTDNSYXpvQWdtS1BGejl4YnAtRTFDTGVCRGpUX0xvaWxiTXl3dlE1ZDNKQ1ZOLTdfaDlZY01ROFV6Q2lBeWo3WFRjcTA0UDM3ZGZyR3h5aVpxWEl1M2VkMkowTjdDVHB3d211dkEtRFN0WmtxazRWRHE5MTFoNk1IWXRLNQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals Advances RSV Drug to Phase 2/3 Trial After US FDA Meeting", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/enanta-pharmaceuticals-advances-rsv-drug-114145262.html", "source_name": "MT Newswires", "published_at": "2026-06-18T11:41:45+00:00", "published_display": "18 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/enanta-pharmaceuticals-announces-advancement-zelicapavir-110000242.html", "source_name": "Business Wire", "published_at": "2026-06-18T11:00:00+00:00", "published_display": "18 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta pushes RSV drug zelicapavir into adult and pediatric trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOdmlwRDA5NHl2Wjc2Tk5reEdtbzVuRl9pOFdDOU03R3F3MjhKck1SV1BETy10WDVncGg1czl3UEg5QXZOdVR5Z0xJSzd3NU8zU08zNTd4bFZKSC1MNE9EVUJVZlljLXVNUGV6OV8zd2dFT2NSUUtVMlNEVkoyZWRrSlhLdG1MMzhDNno3YTJRbXJLOEF1aW5UMjUyUWlLQUI5ZDJiSExBTUZtdEpNdzF2bFZrRWprZ1JralE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals stock rises on RSV drug trial plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPVkNnZmM5WFBlVE1pSUNlbUd0bzhRUUpYQUI4N1RoNU1JSGh4MmVJNXkwVkJMZWgyN1BIbTdVbV9uVDFSYWVRcEZnZTEzR1JUVTlKMTVnTEJSdVpCM0RWOEM1cVc3OGxDcGZvUFdYd0pZYkVIRlo3WVFFNTR4UTNmMVc5NnVKVm9oaFMweEs3RW5MVWV3QVZwbWFVX01sbkJyZ2U2UV80eVkzaGNuX3ZjbTdLY0pjNUV3MDNJSA?oc=5", "source_name": "Investing.com", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQRncwTVZhX2lyQ29RbXRvd0RXdGtKS1ZyUVRkMDZjWS1SSTlIaUFTNEZtc1VLS21USFVPTUxrbkpVellQMndEbGZ6NnRka3JiLWtaSTZaTHdrSE1CQVE0aGZ1TUNxVWxIbW9FNzZOOTBaMU82bmdJTmIwNEQxWWp4a0VVUHUwOXRyX3hTZF96dzZ6dVFBSWx5d1UxQTJoX3dIMGlxSFRIZFF1d1ZQRVZrNkIxU2hOX1l6bWVRWkwtNjZhUFpvQS1JdVJBM0stR0xzWUE?oc=5", "source_name": "Business Wire", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enanta Pharmaceuticals (ENTA) Q2 Loss Improvement Tests Bearish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/enanta-pharmaceuticals-fiscal-q2-earnings-200706784.html", "source_name": "Associated Press", "published_at": "2026-05-11T20:07:06+00:00", "published_display": "11 May 2026 20:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNLUJXRkxoZDY2b0dEN1ZBSmtieHZ3YzNHZVA4SHgwR3ZoQUlmU25EZnFpNGg3Y2ljc0pCTmFldElvRHE5TWRRZzlBSHdwQmRwbEpUMUxTUk1lOXVlSGlmYm80bkV3RmRGaTJhRnlPb2JSR2pRYXhnNzBjUnVrZEplSTRqaWJwdV9UdTJFcElXOXZuYlQwTmtoajFfOHdUNDVDYWc1bmtxM3dHb0ZMMTV3ZFNjSGYzOXBtQ29BYl9VYzc0a09EUWNoWkVjQ3U0UEczc1FfbGJnajJPLXZsTHJJQlJlZHRIZWpCSUh3?oc=5", "source_name": "Business Wire", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZHJfSm1MYUhtM0JqYXJQQ1V3LVF3M0VlbUlCMmVZdHFGTmFYYnhTYjQ5Z3pFemlzVFFBSmhsbmFTeXAzN1UzcXgzSENLVWNhRVBoR042SFFoUFBnejVYMjZabEloM3VOUkotMjJkSmdybWtQTnV4OWFRMDlwMkl6WnphZlNBbDc4LTk0N0JPSzFZTkM4TWxnNVFhRl85MHZMWHNRamR6RF9zS0E?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNZFZCUDJuaXNmRVN6XzhwY1o0WTlNNXQzbWYyYlJDekNNdmc1TkI4dU84RkZhR3RiLVViY3JoMC1zVmZMM0tpMG12MDgtcHRGX2daeEVSajdVNFQ0d1M2RUVTUlZEYXljSnpSSUg4SC16UG5OTWVWVGV5NWNNNU5US2ZCemhpLXRwSVdnQW9PRlRXcUhPcjVqdF9hWW1zYllGQlE?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQeml6cGZTUUF5WTYtM1dwem0zUzBqZV8xMjF3aHhCeDBhRjVNRHFwSVpvU1paWXF6enFWaEdPNzlhd1NqTG8tQ3hUY2EzcjdFeUNTd2liRjVEbENvX1BBLWNVYTZEbkxxUXBqbVk3Y2YyVjdfWEpyVzhhTzljdjZrNWc1N1huX3JRWm1F?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-20T08:00:00+00:00", "published_display": "20 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxQYTlRTzFUOTN0SW9vZm1YcUFkMDVYRk8xQmdQS2U2ZzFBejdJdGhUV2NQSnEzSTFBblVGYVVBNHAzT3lUQzdiTVZ3Q2FfUUpxYjlnV1RoYTZGTWZXUF9QclZZUFd5R1RocEo2cWNFRFpHZ0gzWjk2UW8wQXZ5aTFpalNhSW9aSkx4TmVxekRSdmt4SnJxdTN4OHprTVVpRXZfUHU5VmdnR0FiMnBFX0w5WEFQZnFJSGpqV3JNbmZQYlRHZTJmYkNIOWJzTW9HajNKTlE0cTZweFdTaXZMMFJlc2tHbURfenU4blU4b3ZHOGJ6eWpxTVJBYi1HdzQ?oc=5", "source_name": "Business Wire", "published_at": "2025-11-17T08:00:00+00:00", "published_display": "17 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOZFB2Y3lnOFY0dDNsYlBINzNFRmNFY2llWTRaNDhoQmw2b09rT25POXp2SFEtQ2piMExSVU53UUFWYjFxUE9uNm4zS1U0RzBXd01JYWNTUW1IYzU5dnF2cWlSTlZUMHBFVUVoUGdycW5vZjhOVVh5N2ZQaFQwdXRDRWRqQlNEZEtqeXdnM1NPb05sODY2N1Nuc1hlczQ5c0FnRTVRTmFkallUYzRnbGZoaTFUUEVUY1h3dEFzd1M1dWhTQkphTVVqck5R?oc=5", "source_name": "Business Wire", "published_at": "2025-09-30T07:00:00+00:00", "published_display": "30 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. \u2013 NASDAQ:ENTA", "summary": "The article provides financial data for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), specifically focusing on its enterprise value to EBITDA forward. It indicates the stock market status as closed with no trades. The document highlights the data sources and copyright information ", "url": "https://www.tradingview.com/symbols/NASDAQ-ENTA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-15T00:13:31", "published_display": "15 Jul 2026 00:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. \u2013 DUS:9EP", "summary": "The article focuses on the enterprise value to EBIT forward for Enanta Pharmaceuticals, Inc. (DUS:9EP) as listed on the Dusseldorf Stock Exchange. It provides a financial overview, though no specific values are present, and highlights the company's listing within the Health Techn", "url": "https://www.tradingview.com/symbols/DUS-9EP/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T15:09:30", "published_display": "08 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. \u2013 SWB:9EP", "summary": "This page on TradingView provides financial information for Enanta Pharmaceuticals, Inc. (SWB:9EP), focusing on its enterprise value to forward EBITDA. The content is primarily an outline for financial data and analysis tools available on the platform, without detailed numerical ", "url": "https://www.tradingview.com/symbols/SWB-9EP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T13:40:53", "published_display": "08 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. \u2013 DUS:9EP", "summary": "This page provides financial data, specifically the Enterprise Value to EBITDA forward, for Enanta Pharmaceuticals, Inc. (9EP) traded on the Dusseldorf Stock Exchange. It appears to be a financial data snippet from TradingView, offering a quick overview without detailed analysis ", "url": "https://www.tradingview.com/symbols/DUS-9EP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T11:39:54", "published_display": "08 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals outlines its antiviral pipeline as investors weigh long-term prospects", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNbjR3dWJPN0psTzBxWE1iZEVlUG1DdjJFV0Etc1R4RFl4VXlQRVk2Vlp3OUhQUm5nRk4wNEJCa0ctelhCcHJrWGF0UElrRG1HMXJ3MDg5TDlZaUQ5MXI2dVdhdDhnTG1LLWlYNjVWZTRFaWw4WnZMek10dFZ6YWZoQWhaM3FkTlpzX3MyTnNiSlN2UW9zazJKd2FnRERtdVZSOUpyd09iRmtXa3YyV3c5YzFnU1JWR2lWV29ydThsNmtsRUZxcnMzaS1UYkg?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-07T16:02:36+00:00", "published_display": "07 Jul 2026 16:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. \u2013 GETTEX:9EP", "summary": "This page from TradingView displays financial information for Enanta Pharmaceuticals, Inc. (GETTEX:9EP), specifically focusing on its Enterprise Value to EBITDA forward metric. The content indicates that the market is currently closed, and no trades have occurred for this stock.", "url": "https://www.tradingview.com/symbols/GETTEX-9EP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T12:09:26", "published_display": "06 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. \u2013 GETTEX:9EP", "summary": "This page provides financial data for Enanta Pharmaceuticals, Inc. (GETTEX:9EP), specifically focusing on its enterprise value to EBIT forward. The content is hosted on TradingView, a platform offering various financial tools and market data, and includes legal disclaimers about ", "url": "https://www.tradingview.com/symbols/GETTEX-9EP/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T10:42:09", "published_display": "06 Jul 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals outlines its antiviral pipeline. Focus on long-term opportunities for ENTA st", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOTGhTa3U1UnlESzZjSGM3U3lqX0tkV0dGTDVST3ptUmhmVHo2TVhGODhXZW5mdXg4ODgwMHBJWXFCRTdhMHQ1bmVUZ3hpdDIxbUVrbkt3Qng2dEtHVGZxZzl1SnhYaERpNGVYZVBFdEVKaEc1M1I4cWNzWGo3Tm15WXJpRkUtcENIQWZQc2pUZURBbV9RRFVkVnJnMS1WY1R0bWFzekNHNGxDcXlScUJ5TFJ1YTRKNDNzTEVtNXZ1cFVZVC1MSTR5MkFDTVY?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-03T14:18:42+00:00", "published_display": "03 Jul 2026 14:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 Enanta Pharmaceuticals Inc For: 2 July By Investing.com", "summary": "This article announces the filing of Form 424B5 for Enanta Pharmaceuticals Inc. on July 2nd. It provides basic information about the filing and includes irrelevant market data and news headlines, typical of an Investing.com article.", "url": "https://ca.investing.com/news/stock-market-news/form-424b5-enanta-pharmaceuticals-inc-for-2-july-93CH-4719116", "source_name": "Investing.com Canada", "published_at": "2026-07-03T00:12:21", "published_display": "03 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Enters $75 Million At-the-Market Stock Offering Agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPMHBSNkZjaFl0UHJ5c3hnUlM2NkZESHZOTFYydDlJS0lEU1FsRXI1VVBHVlpWOUpMem5VQjFjZlZmZW1adG9QVTZIN1RKS1h5eEJmV2ZXS2hybXRZdFJtbUhiVUlZWU9RaFVnU3JBQVV2T1QwdDJBYnkycktPaEhhUm5PaVZQLXJuRlZsRlZMc2VtZUtLb29lOFZDSW95MGplQlFiUi1xV3Q?oc=5", "source_name": "Moomoo", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Enanta Pharmaceuticals, Inc. \u2013 NASDAQ:ENTA", "summary": "This page on TradingView.com focuses on the \"Price to sales forward\" metric for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). It provides financial data and an overview of the company's valuation, indicating information about the market performance and financial health of Enanta P", "url": "https://www.tradingview.com/symbols/NASDAQ-ENTA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T15:40:36", "published_display": "01 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Small Cap Comp Growth Benchmark", "summary": "Enanta Pharmaceuticals, Inc. (NasdaqGS: ENTA) has been added to the Russell Small Cap Comp Growth Benchmark, as well as the Russell 2500 Growth and Russell 2000 Growth Benchmarks. This inclusion indicates recognition of the company's growth potential within the small-cap market. ", "url": "https://www.marketscreener.com/news/enanta-pharmaceuticals-inc-nasdaqgs-enta-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdd81f721", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:10:48", "published_display": "29 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 2500 Growth Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQbEhtSklIZzliS1IwUm9BdkpMTlczSFJRUkZRRXNPWEt0Ti12dnBhWU92c0NobFhfRjNzM1BhNms2U2dIc0tlckVzbE9UYk5xS00xS3AwQjlzQjVRaEdYcnhVNzJRZUFOM0lTMlJwS2xyakxFWFE2THFSLU1vdE01a0NaRkFDdU9mU0d1WGdRWEh1UTNqT1BVUlFmaGRYbUJwR19OMkIyVnpjSlF3d1hieU1SSEJRZjl2cUxGbkx6cmMyWjI4ZTU0Z1pncFo?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 3000E Growth Benchmark", "summary": "Enanta Pharmaceuticals, Inc. (NasdaqGS: ENTA) has been added to the Russell 3000E Growth Benchmark. The clinical-stage biotechnology company, focused on virology and immunology, saw its stock rise by 4.09% to 14.00 USD. This inclusion highlights the company's growth potential and", "url": "https://www.marketscreener.com/news/enanta-pharmaceuticals-inc-nasdaqgs-enta-added-to-russell-3000e-growth-benchmark-ce7f5fdeda88f523", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T03:40:57", "published_display": "29 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Vance Terry", "summary": "This article is a statement of changes in beneficial ownership of securities for Enanta Pharmaceuticals, specifically pertaining to Director Vance Terry. It is a regulatory filing indicating transactions related to his holdings in the company.", "url": "https://www.moomoo.com/news/notice/306660384/enanta-pharmaceuticals-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-28T23:40:36", "published_display": "28 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals | SCHEDULE 13G/A: Others", "summary": "This article indicates that a SCHEDULE 13G/A filing related to Enanta Pharmaceuticals (ENTA) has been submitted into the public record. The filing is categorized under \"Others,\" suggesting a beneficial ownership report from a passive investor or another type of filer.", "url": "https://www.moomoo.com/news/notice/306757153/enanta-pharmaceuticals-schedule-13g-a-others", "source_name": "Moomoo", "published_at": "2026-06-28T23:38:58", "published_display": "28 Jun 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 3000 Growth Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPdWdhZ1AwbWp4TFpUcnlYbFF5cDhSSkh6UzUtck1RUVlQZXlsbm1lem9NZ3ZoSEdoYTRCOGZDbnpOaEdidl92clhKckZVYV9Nb096dVVLeGN1dzZCWjdQS2pQaThkbjFVVDB3bTZhZGFVeG0tcGRKYWxzY092dWJ5eEJ0aDg2WG14X2d4RHNRMHRPdHlmSzhNVHVUWGNrMlNLYXVhY1lCY1g3cEhBSW1pcTg2dWItelpvNURDeFZqSzZNbzJDRHdMWFFHSXQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ENTA)", "summary": "This article provides financial actuals and estimates for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), including stock price performance, analyst forecasts, earnings, revenue, and market capitalization. It highlights the company's historical stock prices, volatility, and upcoming", "url": "https://www.tradingview.com/symbols/NASDAQ-ENTA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:50", "published_display": "26 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Enanta Pharmaceuticals, Inc. \u2013 TRADEGATE:9EP", "summary": "This article focuses on the enterprise value to revenue forward for Enanta Pharmaceuticals, Inc. (TRADEGATE:9EP). It lists the company's trading information on the Tradegate Exchange, indicating that the market is currently closed with no trades. The piece is primarily a financia", "url": "https://www.tradingview.com/symbols/TRADEGATE-9EP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:50", "published_display": "26 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Enanta Pharmaceuticals, Inc. \u2013 NASDAQ:ENTA", "summary": "This article provides the \"Price to book forward\" for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). It is a finance-related snippet from TradingView, indicating a focus on financial metrics for the company. The content itself is minimalist, primarily showcasing the title and conte", "url": "https://www.tradingview.com/symbols/NASDAQ-ENTA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:50", "published_display": "26 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals, Inc. Actuals & Estimates (FWB:9EP)", "summary": "This article provides an overview of Enanta Pharmaceuticals, Inc. (FWB:9EP) financials, analyst forecasts, and historical stock performance. It includes details on past earnings, revenue, EBITDA, and provides predictions for future financial results, noting that the company does ", "url": "https://www.tradingview.com/symbols/FWB-9EP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T04:10:30", "published_display": "26 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENTA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Enanta Pharmaceuticals, Inc. (ENTA) stock, including analyst price targets, historical performance, and key financial data. Eight analysts have provided 1-year price forecasts, with a maximum estimate of $32.00 and a minimum of $14.00. The com", "url": "https://www.tradingview.com/symbols/NASDAQ-ENTA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T22:10:50", "published_display": "25 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Enanta Pharmaceuticals, Inc. \u2013 NASDAQ:ENTA", "summary": "This article displays the \"Price to earnings forward\" metric for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). It presents financial data for the company, accessible through TradingView, and includes general market and company information. The content primarily focuses on the stoc", "url": "https://www.tradingview.com/symbols/NASDAQ-ENTA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:10:04", "published_display": "25 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Enanta Pharmaceuticals, Inc. \u2013 TRADEGATE:9EP", "summary": "This article provides financial information for Enanta Pharmaceuticals, Inc. (TRADEGATE:9EP), specifically focusing on its price to book forward value. The data is available through TradingView, which aggregates market and reference data from various providers.", "url": "https://www.tradingview.com/symbols/TRADEGATE-9EP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T17:09:50", "published_display": "25 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?", "summary": "Enanta Pharmaceuticals (ENTA) saw its shares rally 5.2% after its partner, AbbVie, received European Commission approval for Maviret to treat acute hepatitis C. Enanta receives royalties from Maviret's sales. Despite the immediate bump, the stock's future strength is uncertain as", "url": "https://sg.finance.yahoo.com/news/enanta-pharmaceuticals-enta-moves-5-131300518.html", "source_name": "Market source", "published_at": "2026-06-24T13:39:50", "published_display": "24 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Files Appeal in Ongoing Patent Dispute With Pfizer Over Paxlovid", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/enanta-files-appeal-ongoing-patent-102036139.html", "source_name": "MT Newswires", "published_at": "2026-06-24T10:20:36+00:00", "published_display": "24 Jun 2026 10:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EC approves label expansion for Enanta\u2019s Maviret in acute HCV infection", "summary": "The European Commission (EC) has approved Maviret (glecaprevir/pibrentasvir) for treating acute hepatitis C virus (HCV) infection in adults and children aged three years and older. This approval makes Maviret the only treatment available in the EU for both acute and chronic HCV i", "url": "https://www.thepharmaletter.com/pharma-news/ec-approves-label-expansion-for-enanta-s-maviret-in-acute-hcv-infection", "source_name": "The Pharmaletter", "published_at": "2026-06-24T10:39:50", "published_display": "24 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Enanta Pharmaceuticals Inc For: 23 June", "summary": "This article reports on an SEC Form 8K filing by Enanta Pharmaceuticals Inc for June 23. It states that the information provided is not necessarily real-time or accurate and advises readers about the high risks associated with trading financial instruments and cryptocurrencies. T", "url": "https://m.uk.investing.com/news/stock-market-news/form-8k-enanta-pharmaceuticals-inc-for-23-june-93CH-4741365?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-24T04:39:50", "published_display": "24 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Enanta Pharmaceuticals Inc For: 23 June By Investing.com", "summary": "This article reports that Enanta Pharmaceuticals Inc. filed a Form 8K on June 23. The filing is an important regulatory disclosure for public companies. The article provides the title of the filing and mentions the company's stock symbol ENTA, which had a 4.09% increase.", "url": "https://ng.investing.com/news/stock-market-news/form-8k-enanta-pharmaceuticals-inc-for-23-june-93CH-2571085", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T22:39:53", "published_display": "23 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] ENANTA PHARMACEUTICALS INC Reports Material Event", "summary": "Enanta Pharmaceuticals, Inc. (ENTA) reported via an 8-K filing that the United States Court of Appeals for the Federal Circuit affirmed a prior summary judgment ruling, invalidating Enanta's U.S. Patent No. 11,358,953. This patent was related to Pfizer Inc.'s COVID-19 antiviral, ", "url": "https://www.stocktitan.net/sec-filings/ENTA/8-k-enanta-pharmaceuticals-inc-reports-material-event-55a5dd1ee466.html", "source_name": "Stock Titan", "published_at": "2026-06-23T22:10:50", "published_display": "23 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAFC Affirms Enanta Coronavirus Patent Invalid for Lack of Written Description Support in Provisional Application", "summary": "The U.S. Court of Appeals for the Federal Circuit (CAFC) has affirmed the invalidity of Enanta Pharmaceuticals, Inc.'s U.S. Patent 11,358,953 due to a lack of written description support in its provisional application. This decision means the patent cannot claim the earlier prior", "url": "https://ipwatchdog.com/2026/06/23/cafc-affirms-enanta-coronavirus-patent-invalid-lack-written-description-support-provisional-application/", "source_name": "IPWatchdog.com", "published_at": "2026-06-23T18:11:15", "published_display": "23 Jun 2026 18:11", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Enanta stock rating on FDA alignment", "summary": "H.C. Wainwright maintained a Buy rating and $20.00 price target for Enanta Pharmaceuticals (NASDAQ:ENTA) following the FDA's alignment on zelicapavir, which significantly reduces regulatory uncertainty for the RSV drug. Enanta also announced plans for late-stage clinical trials f", "url": "https://m.investing.com/news/analyst-ratings/hc-wainwright-reiterates-enanta-stock-rating-on-fda-alignment-93CH-4755287?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-23T12:11:09", "published_display": "23 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals\u2019 Partner AbbVie Receives European Commission Approval of MAVIRET\u00ae (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus", "summary": "Enanta Pharmaceuticals announced that its partner AbbVie received European Commission approval for MAVIRET\u00ae (glecaprevir/pibrentasvir) to treat acute Hepatitis C Virus (HCV) infection in adults and children aged 3 years and older. This makes MAVIRET the only EU-approved treatment", "url": "https://www.biospace.com/press-releases/enanta-pharmaceuticals-partner-abbvie-receives-european-commission-approval-of-maviret-glecaprevir-pibrentasvir-for-people-with-acute-hepatitis-c-virus", "source_name": "BioSpace", "published_at": "2026-06-23T11:11:09", "published_display": "23 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 89, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals\u2019 Partner AbbVie Receives European Commission Approval of MAVIRET", "summary": "The European Commission has approved MAVIRET (glecaprevir/pibrentasvir), developed by AbbVie with glecaprevir discovered by Enanta Pharmaceuticals, for treating acute Hepatitis C Virus (HCV) infection in adults and children aged 3 and older. This makes MAVIRET the only treatment ", "url": "https://www.businesswire.com/news/home/20260619262507/en/Enanta-Pharmaceuticals-Partner-AbbVie-Receives-European-Commission-Approval-of-MAVIRET-GlecaprevirPibrentasvir-for-People-with-Acute-Hepatitis-C-Virus", "source_name": "Business Wire", "published_at": "2026-06-23T09:11:09", "published_display": "23 Jun 2026 09:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Federal appeals court upholds invalidity of Enanta patent in Pfizer case", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQdHZibmZ3YVhHLVFyeFBRZzFib1ZZWVFOUkRGaWlCbFhvOVRjeWlvT0dkLUJRRFNRMEFGcHRBWmVDWDN1bjZrMUpZdU0zYmtsVDkxV1lhLTBVWVhqckNwejNkNF9oR2UtQzFfM0daajIzc0JYa1JLZ3REc19Qempaai01bng5ZUNMUVhKQ2NuSHc2ZUZ6RmpBZi1TOHB2ZWQwM1dfTHdvaHpka1JyUkN6c1lHOUdkaEo0SEtGSTN5Wktza1pjWk5nRkVXdTEzdw?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta partner AbbVie secures EU approval for MAVIRET in acute HCV", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOSEVhblhLU19TS3NDTzlER2FnNGEzc0xQWnlhVmV3ZTBMNmZzX3Z1c0wwamU5eDRGeTNrWWRqdjVWMHUtc3U4M3NRSWdhanBYYkVabnFmY2ZCbjRhSExqMDZWVG9tTUN0LXlIcDFDNFFwTFhKeUZnZFREb0VNSENDYmFfZEVZVHNhOUxvQTBtOUZUWkZnYUdSSmVBMXItNDByWHlqOVNfcUxqUGVKS1hSQXFUWl9MV0tJRlJsWDdiRQ?oc=5", "source_name": "scanx.trade", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pfizer patent win against Enanta over COVID pill upheld by appeals court", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQbUNZUG1EYndSTDNSYXpvQWdtS1BGejl4YnAtRTFDTGVCRGpUX0xvaWxiTXl3dlE1ZDNKQ1ZOLTdfaDlZY01ROFV6Q2lBeWo3WFRjcTA0UDM3ZGZyR3h5aVpxWEl1M2VkMkowTjdDVHB3d211dkEtRFN0WmtxazRWRHE5MTFoNk1IWXRLNQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals Advances RSV Drug to Phase 2/3 Trial After US FDA Meeting", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/enanta-pharmaceuticals-advances-rsv-drug-114145262.html", "source_name": "MT Newswires", "published_at": "2026-06-18T11:41:45+00:00", "published_display": "18 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/enanta-pharmaceuticals-announces-advancement-zelicapavir-110000242.html", "source_name": "Business Wire", "published_at": "2026-06-18T11:00:00+00:00", "published_display": "18 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta pushes RSV drug zelicapavir into adult and pediatric trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOdmlwRDA5NHl2Wjc2Tk5reEdtbzVuRl9pOFdDOU03R3F3MjhKck1SV1BETy10WDVncGg1czl3UEg5QXZOdVR5Z0xJSzd3NU8zU08zNTd4bFZKSC1MNE9EVUJVZlljLXVNUGV6OV8zd2dFT2NSUUtVMlNEVkoyZWRrSlhLdG1MMzhDNno3YTJRbXJLOEF1aW5UMjUyUWlLQUI5ZDJiSExBTUZtdEpNdzF2bFZrRWprZ1JralE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals stock rises on RSV drug trial plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPVkNnZmM5WFBlVE1pSUNlbUd0bzhRUUpYQUI4N1RoNU1JSGh4MmVJNXkwVkJMZWgyN1BIbTdVbV9uVDFSYWVRcEZnZTEzR1JUVTlKMTVnTEJSdVpCM0RWOEM1cVc3OGxDcGZvUFdYd0pZYkVIRlo3WVFFNTR4UTNmMVc5NnVKVm9oaFMweEs3RW5MVWV3QVZwbWFVX01sbkJyZ2U2UV80eVkzaGNuX3ZjbTdLY0pjNUV3MDNJSA?oc=5", "source_name": "Investing.com", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQRncwTVZhX2lyQ29RbXRvd0RXdGtKS1ZyUVRkMDZjWS1SSTlIaUFTNEZtc1VLS21USFVPTUxrbkpVellQMndEbGZ6NnRka3JiLWtaSTZaTHdrSE1CQVE0aGZ1TUNxVWxIbW9FNzZOOTBaMU82bmdJTmIwNEQxWWp4a0VVUHUwOXRyX3hTZF96dzZ6dVFBSWx5d1UxQTJoX3dIMGlxSFRIZFF1d1ZQRVZrNkIxU2hOX1l6bWVRWkwtNjZhUFpvQS1JdVJBM0stR0xzWUE?oc=5", "source_name": "Business Wire", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals (ENTA) Q2 Loss Improvement Tests Bearish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxONzdHZE96bU1OT3RUeFZyd2pEVTBTSTQ0WXV4Z1J6QVBiRVdLOS01YmVVTzYtSlIweENwbEhIbVBqcU1oMkF4TjhJOHkyaFJMUnJWTnRoa29OVGhmeWZhWkZjcnJxNXJNYnE5TE4tajBzY1hCMzltYW9kRTFDRkJDeUFNYk45a2FJR01zclhzTU9Tb18zQ2Q0S3Jka1JUVmIzb3BzOFduS05DcTRBWjRqNGZrRk9naC1jeVFtUzVxbndFOFpEUW9RcUVlYjBCVHQ5Vm5Hd1BaUjJCUGRPVUE4VzhIT0psZFlmRTdabFhWVdIB9AFBVV95cUxNRDI5NlZFZzVhM2tmS0xaeFk0anRoaC13UXNuUjFfeVFIbjN0N0JyZ1FiZ2RQbUY1aW9fcG12aHQ1b3NrZmp2c2ZJTHZVcXFqeHN3TXVESmYwcjJzOGtYYWtXMGE2MUVVOUpSRmZlZDVXS0ZLRGJNbHl6NjFDb1F2cHdiZXhmSUw3S3Y5YmdUTnRDc04yS2swRDR5T2ZJTm1KNVF0NDZWRElrdlFVem1ZTDFLWmxESndINUFOQ2pETTlubEpCQWh5YWNhVDZyZUxLZzVhWWZldDhnbzhNbFAzem9pQWNPMk91ckpSSGhzV3RscDVk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/enanta-pharmaceuticals-fiscal-q2-earnings-200706784.html", "source_name": "Associated Press", "published_at": "2026-05-11T20:07:06+00:00", "published_display": "11 May 2026 20:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNLUJXRkxoZDY2b0dEN1ZBSmtieHZ3YzNHZVA4SHgwR3ZoQUlmU25EZnFpNGg3Y2ljc0pCTmFldElvRHE5TWRRZzlBSHdwQmRwbEpUMUxTUk1lOXVlSGlmYm80bkV3RmRGaTJhRnlPb2JSR2pRYXhnNzBjUnVrZEplSTRqaWJwdV9UdTJFcElXOXZuYlQwTmtoajFfOHdUNDVDYWc1bmtxM3dHb0ZMMTV3ZFNjSGYzOXBtQ29BYl9VYzc0a09EUWNoWkVjQ3U0UEczc1FfbGJnajJPLXZsTHJJQlJlZHRIZWpCSUh3?oc=5", "source_name": "Business Wire", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZHJfSm1MYUhtM0JqYXJQQ1V3LVF3M0VlbUlCMmVZdHFGTmFYYnhTYjQ5Z3pFemlzVFFBSmhsbmFTeXAzN1UzcXgzSENLVWNhRVBoR042SFFoUFBnejVYMjZabEloM3VOUkotMjJkSmdybWtQTnV4OWFRMDlwMkl6WnphZlNBbDc4LTk0N0JPSzFZTkM4TWxnNVFhRl85MHZMWHNRamR6RF9zS0E?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNZFZCUDJuaXNmRVN6XzhwY1o0WTlNNXQzbWYyYlJDekNNdmc1TkI4dU84RkZhR3RiLVViY3JoMC1zVmZMM0tpMG12MDgtcHRGX2daeEVSajdVNFQ0d1M2RUVTUlZEYXljSnpSSUg4SC16UG5OTWVWVGV5NWNNNU5US2ZCemhpLXRwSVdnQW9PRlRXcUhPcjVqdF9hWW1zYllGQlE?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQeml6cGZTUUF5WTYtM1dwem0zUzBqZV8xMjF3aHhCeDBhRjVNRHFwSVpvU1paWXF6enFWaEdPNzlhd1NqTG8tQ3hUY2EzcjdFeUNTd2liRjVEbENvX1BBLWNVYTZEbkxxUXBqbVk3Y2YyVjdfWEpyVzhhTzljdjZrNWc1N1huX3JRWm1F?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-20T08:00:00+00:00", "published_display": "20 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxQYTlRTzFUOTN0SW9vZm1YcUFkMDVYRk8xQmdQS2U2ZzFBejdJdGhUV2NQSnEzSTFBblVGYVVBNHAzT3lUQzdiTVZ3Q2FfUUpxYjlnV1RoYTZGTWZXUF9QclZZUFd5R1RocEo2cWNFRFpHZ0gzWjk2UW8wQXZ5aTFpalNhSW9aSkx4TmVxekRSdmt4SnJxdTN4OHprTVVpRXZfUHU5VmdnR0FiMnBFX0w5WEFQZnFJSGpqV3JNbmZQYlRHZTJmYkNIOWJzTW9HajNKTlE0cTZweFdTaXZMMFJlc2tHbURfenU4blU4b3ZHOGJ6eWpxTVJBYi1HdzQ?oc=5", "source_name": "Business Wire", "published_at": "2025-11-17T08:00:00+00:00", "published_display": "17 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOZFB2Y3lnOFY0dDNsYlBINzNFRmNFY2llWTRaNDhoQmw2b09rT25POXp2SFEtQ2piMExSVU53UUFWYjFxUE9uNm4zS1U0RzBXd01JYWNTUW1IYzU5dnF2cWlSTlZUMHBFVUVoUGdycW5vZjhOVVh5N2ZQaFQwdXRDRWRqQlNEZEtqeXdnM1NPb05sODY2N1Nuc1hlczQ5c0FnRTVRTmFkallUYzRnbGZoaTFUUEVUY1h3dEFzd1M1dWhTQkphTVVqck5R?oc=5", "source_name": "Business Wire", "published_at": "2025-09-30T07:00:00+00:00", "published_display": "30 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 63, "sentiment_summary": {"positive": 14, "negative": 4, "neutral": 45, "score": 54, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 20.7, "count": 37}, {"event": "earnings", "label": "Earnings", "weight": 8.6, "count": 17}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.85, "count": 7}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}], "positive_events": 14, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 13.7, "latest_week": "2026-07-10", "one_week_move": -9.3, "four_week_move": 15.1, "twelve_week_move": -2.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.030273, "market_dynamics_buy_signal": false, "relative_strength": -2.070019, "fair_value_gap": 23.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 46.3528, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.3% over one week, +15.1% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 15}, {"label": "Market source", "count": 9}, {"label": "Business Wire", "count": 6}, {"label": "simplywall.st", "count": 5}, {"label": "Moomoo", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "Ad Hoc News", "count": 2}, {"label": "Investing.com Canada", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 55}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 37}, {"label": "Earnings", "count": 17}, {"label": "Regulatory and legal", "count": 7}, {"label": "Analyst action", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "55", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-9.3% over one week, +15.1% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. \u2013 NASDAQ:ENTA"}], "updated_at": "2026-07-16T11:53:45.457436+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}